Literature DB >> 8609278

The outcomes movement and new measures of the severity of psoriasis.

K E Mckenna1, R S Stern.   

Abstract

Traditionally physicians have assessed the severity of psoriasis on the basis of involved surface area or other physical features. These measures are not highly reliable and do not quantify the extent to which the disease affects the patient. New approaches to health care assessment have been developed, including evaluation of the outcome of medical care. This new direction in health care assessment has been described as the "outcomes movement." This emphasizes the assessment of patients' outcomes with respect to quality of life and functional capacity, rather than traditional techniques that rely on the results of physical or laboratory examinations. New measures to assess treatment effectiveness will almost certainly be used to allocate health care resources. We review the status of measures of psoriasis and the implications of newer methods for assessing disease impact and outcomes of therapy.

Entities:  

Mesh:

Year:  1996        PMID: 8609278     DOI: 10.1016/s0190-9622(96)90469-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

2.  Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial.

Authors:  R Anderson; R Rajagopalan
Journal:  Qual Life Res       Date:  1998-12       Impact factor: 4.147

3.  [Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis].

Authors:  I Zschocke; U Hammelmann; M Augustin
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

Review 4.  Psoriasis treatment: current and emerging directed therapies.

Authors:  L S Winterfield; A Menter; K Gordon; A Gottlieb
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

5.  Evaluation of efalizumab using safe psoriasis control.

Authors:  Kim A Papp; Eric Henninger
Journal:  BMC Dermatol       Date:  2006-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.